PKD LIVE - What is Tolvaptan and how does it work?

Dr Grahame Wood, Consultant Renal Physician, Salford Royal Hospital discusses Tolvaptan and how it can be effective in slowing down progression in Autosomal Dominant Polycystic Kidney Disease (ADPKD). ADPKD is a genetic condition where several cysts form and grow on various organs in the body, but mainly the kidneys. Affecting over 12 million people around the world and up to 70,000 adults and children in the UK, ADPKD is the most common genetic kidney disease and the fourth leading cause of kidney failure. There is currently no cure. PKD Charity is the first and only UK charity solely dedicated to improving the lives of people affected by PKD. Since 2000 we’ve been helping individuals and families to live life as fully as possible by providing the best year-round support, tools and inspiration. We’re a small charity with big ambitions; campaigning to improve services, promote understanding, and fund research into discovering better treatments, new treatments, and a cure for PKD. Our close partnerships with clinicians, scientists, other major kidney charities and health authorities mean the information we publish is not only current it’s credible. We work to influence and drive change, giving PKD the strong voice it greatly deserves.